<DOC>
	<DOCNO>NCT01486628</DOCNO>
	<brief_summary>It single dose , single-center , randomize , double-blind , placebo-controlled dose escalation study SC continuously-delivered LD/CD solution ( ND-0612 ) 24 hour healthy volunteer . Objectives determine : 1. maximal tolerate dose SC ND-0612 2. steady state plasma concentration LD CD follow SC ND-0612 administration . Each treatment group include 6 healthy volunteer . Dosing do sequential manner .</brief_summary>
	<brief_title>Study Subcutaneous Continuous Administration Levodopa/Carbidopa Solution ( ND0612 ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy Caucasian male 18 40 year ( inclusive ) age Normal BMI ( 18.524.9 ) Subjects negative urinary drug abuse , HIV , Hepatitis B Hepatitis C serology test Subjects must able adhere protocol requirement Subjects must provide write informed consent participate study . History significant psychiatric disorder , neurological disease sleep disorder History significant systemic disease , medical history test perform screen examination Clinically significant laboratory test screen History drug alcohol abuse . Allergy levodopa , carbidopa inactive component test formulation . Subjects dark skin Subjects skin disease neoplasms Subjects narrowangle glaucoma Subjects significant allergic response drug . Presence clinically significant scar skin disorder area placement pump . Use prescription overthecounter ( OTC ) medication Subjects donate blood receive blood , last 3 month Participation another clinical trial last 30 day Subjects ability communicate well adhere protocol procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>